India's biosimilars growth expected to grow exponentially

Biosimilars market share is expected to grow exponentially over the next few years at a rate of 52% between 2010 and 2015.  Two of the factors leading to this are patent expirations on biologics and the rising cost of drugs. India is also a leader in biosimilars production, with 40 of the biologics marketed in India, 25 of the biologics are manufactured there.  They've also embraced the manufacturing of the drugs due to the cost advantage of development, which reduces the appeal of importing them.  Learn more about the stats above in the Global Biosimilars Market Analysis, which was recently released.

At the Business of Biosimilars and Biobetters Conference taking place September 19-21, 2011 in Boston, MA, Subir Basak, PhD, MBA, Chief Executive Officer, Celestial Biologicals, Chief Commercial Officer, Intas Biopharmaceuticals, will examine how the biosimilars market is expected to evolve in India and the IP and tax implications of their future development.  For more information on this presentation and the others at the Business of Biosimilars and Biobetters Conference, download the brochure here.

Share this article with your social network, just click below to share now!

Share |